Fortunes can change quickly in the volatile biotech industry. And few things can impact drugmakers' performance -- and prospects -- the way regulatory approvals can. That's why it's a good idea for biotech investors to keep an eye on upcoming regulatory decisions.

With that as a backdrop, let's look at two companies that could land green lights from regulators in the U.S. before the end of the year: Gilead Sciences (NASDAQ: GILD) and Provention Bio (NASDAQ: PRVB).

Continue reading

Source Fool.com